What is the appropriate immediate‑release (IR) isosorbide mononitrate dose equivalent to 30 mg extended‑release (ER) for a patient who requires the medication to be crushed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Isosorbide Mononitrate ER 30mg Interchange for Crushed Medication

For a patient requiring crushed medication who is currently on isosorbide mononitrate 30mg extended-release, switch to immediate-release isosorbide mononitrate 20mg twice daily, administered 7 hours apart. 1, 2

Critical Safety Warning

Extended-release isosorbide mononitrate tablets must NOT be crushed or chewed per FDA labeling, as this destroys the controlled-release mechanism and can result in dose dumping with potentially dangerous hypotension. 3

Recommended Conversion Strategy

Immediate-Release Dosing Regimen

  • Start with isosorbide mononitrate immediate-release 20mg twice daily, with doses separated by 7 hours (e.g., 8 AM and 3 PM). 1, 2, 4
  • This asymmetric dosing schedule provides 12-24 hours of antianginal coverage while maintaining a nitrate-free interval overnight to prevent tolerance development. 1, 2
  • The 7-hour separation is critical—do NOT dose every 12 hours, as this promotes rapid tolerance. 5

Rationale for 20mg Twice Daily

  • ACC/AHA guidelines specifically list "isosorbide mononitrate oral 20mg twice daily" as the standard immediate-release regimen with documented 12-24 hour duration of effect. 1, 2
  • The 30mg ER formulation releases 30% immediately (≈9mg) with the remaining 70% (≈21mg) released gradually over 17 hours. 6, 7
  • The 20mg IR twice-daily regimen is the only immediate-release schedule with adequate documentation for maintained 12-hour efficacy during steady-state treatment. 5

Alternative Formulations if Crushing is Required

Sublingual Nitroglycerin for Acute Use

  • Nitroglycerin 0.3-0.6mg sublingual tablets can be used for breakthrough angina and do not require crushing (dissolves under tongue). 1, 2
  • Duration of effect: 1-7 minutes. 1, 2

Transdermal Nitroglycerin for Maintenance

  • Nitroglycerin transdermal patch 0.2-0.8mg/hour applied every 12 hours (with 12-hour patch-free interval overnight) avoids the need for oral administration entirely. 1, 2
  • Provides 8-12 hours of antianginal effect during intermittent therapy. 1, 2

Isosorbide Dinitrate Alternative

  • Isosorbide dinitrate 5-80mg oral, 2-3 times daily is another option if the patient can swallow small tablets whole. 1, 2
  • Duration up to 8 hours per dose. 1, 2

Critical Monitoring Parameters

Blood Pressure Contraindications

  • Absolutely avoid nitrates if systolic BP <90 mmHg or >30 mmHg below baseline. 1, 2, 4
  • Systolic BP should not be titrated below 110 mmHg in previously normotensive patients or >25% below starting mean arterial pressure in hypertensive patients. 1

Drug Interactions

  • Concurrent phosphodiesterase-5 inhibitors are absolutely contraindicated (sildenafil within 24 hours, tadalafil within 48 hours) due to risk of profound hypotension, myocardial infarction, and death. 1, 4

Tolerance Prevention

  • The nitrate-free interval (overnight with morning and afternoon dosing) is essential to prevent hemodynamic tolerance, which typically develops after 24 hours of continuous nitrate exposure. 1
  • Do NOT use continuous 24-hour nitrate coverage, as this leads to loss of efficacy. 1

Common Pitfalls to Avoid

  • Never crush extended-release formulations—this is explicitly contraindicated and dangerous. 3
  • Avoid symmetric 12-hour dosing (e.g., 8 AM and 8 PM) of immediate-release formulations, as this promotes tolerance. 5
  • Do not assume dose equivalence between ER and IR formulations—the 30mg ER does not equal 30mg IR due to different pharmacokinetic profiles. 6, 7
  • Headache is the most common adverse effect (38-57% incidence) but typically improves with continued treatment; consider starting at lower doses for several days before increasing. 3

Special Population Considerations

Heart Failure Patients

  • Isosorbide mononitrate is NOT recommended for heart failure with reduced ejection fraction. 8, 9, 4
  • For HFrEF, only the combination of isosorbide dinitrate 20-40mg plus hydralazine 37.5-75mg three times daily is guideline-recommended, particularly in Black patients. 8, 9, 4

References

Guideline

Isosorbide Mononitrate: Indications, Dosing, and Safety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.